Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Palazestrant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Olema Oncology Reports Q2 2024 Results And Corporate Update
    Olema Oncology Reports Q2 2024 Results And Corporate Update

    06 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/06/2925417/0/en/Olema-Oncology-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    06 Aug 2024
    Share Share
    Olema Presents Promising Palazestrant + Ribociclib Data At ESMO Breast Congress
    Olema Presents Promising Palazestrant + Ribociclib Data At ESMO Breast Congress

    15 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/15/2882291/0/en/Olema-Oncology-Announces-Promising-New-Data-for-Palazestrant-in-Combination-with-Ribociclib-Presented-at-the-2024-ESMO-Breast-Cancer-Congress.html

    GLOBENEWSWIRE
    15 May 2024
    Share Share
    Olema Oncology Q1 2024 Financials, Corporate Update
    Olema Oncology Q1 2024 Financials, Corporate Update

    08 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/08/2878169/0/en/Olema-Oncology-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    08 May 2024
    Share Share
    Olema Palazestrant+Ribociclib Breast Cancer Data At ESMO
    Olema Palazestrant+Ribociclib Breast Cancer Data At ESMO

    08 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/08/2877691/0/en/Olema-Oncology-Announces-New-Clinical-Data-for-Palazestrant-in-Combination-with-Ribociclib-to-be-Presented-at-the-2024-ESMO-Breast-Cancer-Annual-Congress.html

    GLOBENEWSWIRE
    08 May 2024
    Share Share
    Olema Oncology Announces Publication of Data Highlighting Palazestrant™s Ability
    Olema Oncology Announces Publication of Data Highlighting Palazestrant™s Ability

    06 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/03/06/2841269/0/en/Olema-Oncology-Announces-Publication-of-Data-Highlighting-Palazestrant-s-Ability-to-Inhibit-Wild-Type-and-Mutant-ER-Breast-Cancer-Both-as-Monotherapy-and-in-Combination-with-CDK4-6.html

    GLOBENEWSWIRE
    06 Mar 2024
    Share Share
    Olema Announces Palazestrant Demonstrates Combinability with CDK4/6 Inhibitors
    Olema Announces Palazestrant Demonstrates Combinability with CDK4/6 Inhibitors

    05 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/12/05/2791260/0/en/Olema-Oncology-Announces-Palazestrant-Demonstrates-Attractive-Combinability-with-CDK4-6-Inhibitors-Ribociclib-and-Palbociclib-in-Phase-1b-2-Studies.html

    GLOBENEWSWIRE
    05 Dec 2023
    Share Share